Related Experiment Video
Updated: Oct 2, 2026
In vitro Methylation Assay to Study Protein Arginine Methylation
Published on: October 5, 2014
Identification, Synthesis, and Biological Evaluations of Potent Inhibitors Targeting Type I Protein Arginine
Xiao Li1,2,3, Lun Zhang1, Jing Xu1
1College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China.
Abstract:
CARM1 (coactivator-associated arginine methyltransferase 1), which belongs to type I PRMTs (protein arginine methyltransferases), is a potential therapeutic target for treatment of multiple cancers. In this study, we first identified several hit compounds against CARM1 by structure-based virtual screening (IC50 = 35.51 ± 6.68 to 68.70 ± 8.12 μM) and then carried out chemical structural optimizations, leading to six compounds with significantly improved activities targeting CARM1 (IC50 = 18 ± 2 to 107 ± 6 nM). As a compound with an ethylenediamino motif, the most potent inhibitor, ZL-28-6, also exhibited potent inhibition against other type I PRMTs. Compared to the type I PRMT inhibitor from our previous work (DCPR049_12), ZL-28-6 showed increased potency against CARM1 and decreased activity against other type I PRMTs. Moreover, ZL-28-6 showed better antiproliferation activities toward a series of solid tumor cells than DCPR049_12, indicating its broad spectrum of anticancer activity. In addition, cellular thermal shift and Western blot assays validated that ZL-28-6 could target CARM1 in cells. Taken together, the inhibitor we identified could serve as a potent probe for studying CARM1's biological functions and shed light on the future design of novel CARM1 inhibitors with stronger activities and selectivities.
Insights
Researchers identified potent inhibitors targeting coactivator-associated arginine methyltransferase 1 (CARM1), a key protein in cancer. The lead compound, ZL-28-6, shows promising anticancer activity and selectivity, aiding future drug design.
Area of Science:
- Biochemistry
- Medicinal Chemistry
- Oncology
Background:
- Coactivator-associated arginine methyltransferase 1 (CARM1) is a type I protein arginine methyltransferase implicated in various cancers.
- CARM1 represents a potential therapeutic target for developing novel anticancer agents.
Purpose of the Study:
- To identify and optimize small molecule inhibitors targeting CARM1.
- To evaluate the anticancer efficacy and selectivity of the developed CARM1 inhibitors.
Main Methods:
- Structure-based virtual screening was employed to identify initial hit compounds against CARM1.
- Chemical structural optimizations were performed to enhance inhibitor potency and selectivity.
- In vitro assays, including IC50 determination, and cellular assays (thermal shift, Western blot) were used for validation.
Main Results:
- Initial screening yielded hit compounds with moderate CARM1 inhibitory activity (35.51–68.70 μM).
- Optimization led to six potent inhibitors with significantly improved activity (18–107 nM).
- The lead compound, ZL-28-6, demonstrated enhanced potency and selectivity for CARM1 compared to previous inhibitors, alongside broad-spectrum antiproliferation activity against solid tumor cells.
Conclusions:
- The identified inhibitor ZL-28-6 is a potent and selective CARM1 inhibitor with demonstrated anticancer potential.
- This compound can serve as a valuable tool for investigating CARM1's biological roles.
- The findings provide a foundation for designing next-generation CARM1 inhibitors with improved therapeutic profiles.
